tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Autolus Therapeutics Directors Announce Departure Plans

Story Highlights
Autolus Therapeutics Directors Announce Departure Plans

Elevate Your Investing Strategy:

Autolus Therapeutics ( (AUTL) ) has provided an announcement.

On May 23, 2025, Drs. Joseph Anderson and Martin Murphy announced their decision not to seek re-election to the Board of Directors of Autolus Therapeutics at the upcoming Annual General Meeting. Their resignation is not due to any disagreements with the company’s management or board, suggesting a smooth transition and stability within the company’s governance structure.

The most recent analyst rating on (AUTL) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Autolus Therapeutics stock, see the AUTL Stock Forecast page.

Spark’s Take on AUTL Stock

According to Spark, TipRanks’ AI Analyst, AUTL is a Neutral.

Autolus Therapeutics is experiencing strong revenue growth and strategic geographic expansion, notably with AUCATZYL. However, the financial performance indicates significant profitability and cash flow challenges. Technical indicators suggest caution, and while corporate events bolster future prospects, financial sustainability issues and a negative P/E ratio weigh heavily on the stock’s overall score.

To see Spark’s full report on AUTL stock, click here.

More about Autolus Therapeutics

Average Trading Volume: 1,973,309

Technical Sentiment Signal: Sell

Current Market Cap: $465.7M

For an in-depth examination of AUTL stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1